The Dipeptidyl Peptidase-4 Inhibitor Des-Fluoro-Sitagliptin Regulates Brown Adipose Tissue Uncoupling Protein Levels in Mice with Diet-Induced Obesity

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Shimasaki, Takanobu ^a   Masaki, Takayuki ^a   Mitsutomi, Kimihiko ^a   Ueno, Daisuke ^a   Gotoh, Koro ^a   Chiba, Seiichi ^a   Kakuma, Tetsuya ^a   Yoshimatsu, Hironobu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; FATTY ACID; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; LEPTIN; LIPID; MELANOCORTIN 4 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROOPIOMELANOCORTIN; SITAGLIPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ARTICLE; BLOOD SAMPLING; BODY FAT; BODY MASS; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPOTHALAMUS; LIPID DIET; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; RESPIRATORY QUOTIENT; SKELETAL MUSCLE; WEIGHT CHANGE; WESTERN BLOTTING;

ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; ANIMALS; DIETARY FATS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; OBESITY; PPAR GAMMA; PYRAZINES; TRIAZOLES;

EID: 84877839950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063626     Document Type: Article

References (36)

1. Mentlein R, (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24.
2. Thornberry NA, Gallwitz B, (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23: 479-486.
3. Lehrke M, Marx N, (2011) Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8: 382-391.
4. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, et al. (2009) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94: 1843-1852.
5. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, et al. (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246-1257.
6. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA, (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181.
7. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I, (2001) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33: 73-77.
8. Vendrell J, El Bekay R, Peral B, Garcia-Fuentes E, Megia A, et al. (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152: 4072-4079.
9. Polakof S, Miguez JM, Soengas JL, (2011) Evidence for a gut-brain axis used by glucagon-like peptide-1 to elicit hyperglycaemia in fish. J Neuroendocrinol 23: 508-518.
10. Lamont BJ, Drucker DJ, (2008) Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat-Fed Mice. Diabetes 57: 190-198.
11. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, et al. (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Current Medical Research and Opinion® 24: 537-550.
12. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, et al. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet 376: 431-439.
13. Argyropoulos G, Harper ME, (2002) Uncoupling proteins and thermoregulation. J Appl Physiol 92: 2187-2198.
14. Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A, et al. (2001) UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochim Biophys Acta 1504: 82-106.
15. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB, (1997) UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 235: 79-82.
16. Villarroya F, Iglesias R, Giralt M, (2007) PPARs in the Control of Uncoupling Proteins Gene Expression. PPAR Res 2007: 74364.
17. Masaki T, Yoshimichi G, Chiba S, Yasuda T, Noguchi H, et al. (2003) Corticotropin-releasing hormone-mediated pathway of leptin to regulate feeding, adiposity, and uncoupling protein expression in mice. Endocrinology 144: 3547-3554.
18. Mostyn A, Bos PM, Litten JC, Laws J, Symonds ME, et al. (2008) Differential effects of thyroid hormone manipulation and beta adrenoceptor agonist administration on uncoupling protein mRNA abundance in adipose tissue and thermoregulation in neonatal pigs. Organogenesis 4: 182-187.
19. Arakawa M, Masaki T, Nishimura J, Seike M, Yoshimatsu H, (2011) The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. Endocr J 58: 161-170.
20. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
21. Cardoso AR, Queliconi BB, Kowaltowski AJ, (2010) Mitochondrial ion transport pathways: Role in metabolic diseases. Biochimica et Biophysica Acta (BBA)- Bioenergetics 1797: 832-838.
22. Cannon B, Nedergaard J, (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277-359.
23. Himms-Hagen J, Harper M-E, (2001) Physiological Role of UCP3 May Be Export of Fatty Acids from Mitochondria When Fatty Acid Oxidation Predominates: An Hypothesis. Experimental Biology and Medicine 226: 78-84.
24. Mu J, Woods J, Zhou Y-P, Roy RS, Li Z, et al. (2006) Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes. Diabetes 55: 1695-1704.
25. Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, et al. (2012) Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue. Endocrinology 153: 564-573.
26. Richard D, Picard F, (2011) Brown fat biology and thermogenesis. Front Biosci 16: 1233-1260.
27. Zaninovich AA, (2001) [Thyroid hormones, obesity and brown adipose tissue thermogenesis]. Medicina (B Aires) 61: 597-602.
28. Yasuda T, Masaki T, Sakata T, Yoshimatsu H, (2004) Hypothalamic neuronal histamine regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose tissue in rats. Neuroscience 125: 535-540.
29. Morrison CD, Huypens P, Stewart LK, Gettys TW, (2009) Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease 1792: 409-416.
30. Thaler JP, Schwartz MW, (2010) Minireview: Inflammation and Obesity Pathogenesis: The Hypothalamus Heats Up. Endocrinology 151: 4109-4115.
31. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, et al. (2012) Sitagliptin Exerts an Antinflammatory Action. Journal of Clinical Endocrinology & Metabolism 97: 3333-3341.
32. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, et al. (2012) Exenatide Exerts a Potent Antiinflammatory Effect. Journal of Clinical Endocrinology & Metabolism 97: 198-207.
33. Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Ragonesi PD, et al. (2010) Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59: 887-895.
34. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, et al. (2007) Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not. Diabetes 56: 8-15.
35. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 9: 194-205.
36. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556-1568.